Israeli biotech KidneyCure is developing personalized cell-therapy technology for treating advanced chronic kidney disease (CKD). An estimated 30 million adults in the US have CKD (most are undiagnosed) with 600,000 on dialysis.
Israeli charity Ezer Mizion is celebrating the 3,000-milestone for the number of life-saving stem-cell transplants performed as a direct result of its bone-marrow registry. Prior to Ezer Mizion, chances of a Jewish patient finding a genetic match was 8%. Now, 76% of requests receive a positive response.
Israel is number one in the world for medical patents per capita. These patents have led to numerous revolutionary cardiovascular procedures and devices. E.g. aortic valve replacement, mitral valve repair, tiny pacemakers, heart monitoring chips and especially stents.
Israeli NGO JobKatif has established Achotenu - a program at the Hebrew University in Jerusalem’s Hadassah hospital, for Ethiopian-Israelis to earn a degree in nursing and long-term employment. The current program has 58 students including those in this inspiring video.
Israel Technion Professor Hossam Haick received the European Commission Innovation Prize in Lisbon for inventing the SniffPhone, a smartphone device to detect cancer in the breath. He was “the most innovative scientist realizing an idea in the field of electronic systems”.
Israeli NGO 8400 Network is building a network of 400 top Israeli health-tech brains over 8 years (hence 8400). These leaders are using the best practices of global life-sciences ecosystems to initiate projects that promote growth in the health-related industry in Israel.
72-year old Israeli Yehuda lost both legs after an infection and was considering ending his life. But when volunteers from NGO United Hatzalah’s ‘Ten Kavod’ project heard of his plight, they took him swimming in the sea and even on a yacht trip. It has totally changed his life.
Israeli biotech Redhill announced positive top-line results from its confirmatory Phase 3 study using its TALICIA treatment for H. pylori Infection. Of 455 trial participants, the antibiotic-resistant infection was eradicated completely in 85% of cases compared to 58% using an alternative.
Israel’s Teva has received US FDA approval for its Truxima treatment for several conditions of the deadly non-Hodgkin’s lymphoma, a type of blood cancer. Truxima is a bio-similar (tested low-cost alternative) to Rituxan (Rituximab) manufactured by Roche.
Researchers at Israel’s Technion have developed a “toolbox” technique to give organic chemists a cheap and quick method to design complex molecules and make safe medicines. They place smaller molecules in a ring, make them rigid, use a catalyst to break their bonds and re-assemble them like toy bricks.